ClinicalTrials.gov

History of Changes for Study: NCT02935634
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (FRACTION-GC)
Latest version (submitted May 9, 2023) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 October 14, 2016 None (earliest Version on record)
2 October 25, 2016 References, Contacts/Locations, Conditions, Study Status and Study Identification
3 November 30, 2016 Recruitment Status, Study Status and Contacts/Locations
4 December 6, 2016 Contacts/Locations and Study Status
5 December 23, 2016 Contacts/Locations and Study Status
6 January 19, 2017 Study Status
7 January 23, 2017 Contacts/Locations and Study Status
8 February 16, 2017 Contacts/Locations and Study Status
9 March 3, 2017 Contacts/Locations and Study Status
10 March 29, 2017 Contacts/Locations, Study Status, Oversight and References
11 April 17, 2017 Contacts/Locations, Study Status and References
12 May 15, 2017 Contacts/Locations, Study Status and References
13 May 30, 2017 Contacts/Locations, Study Design and Study Status
14 June 30, 2017 Contacts/Locations and Study Status
15 July 18, 2017 Contacts/Locations and Study Status
16 July 31, 2017 Contacts/Locations and Study Status
17 August 15, 2017 Contacts/Locations and Study Status
18 August 30, 2017 Contacts/Locations and Study Status
19 September 1, 2017 Arms and Interventions, Contacts/Locations and Study Status
20 September 15, 2017 Study Status and Contacts/Locations
21 October 4, 2017 Study Status and Contacts/Locations
22 October 17, 2017 Contacts/Locations and Study Status
23 January 31, 2018 Contacts/Locations, Arms and Interventions, Outcome Measures and Study Status
24 February 22, 2018 Contacts/Locations and Study Status
25 March 12, 2018 Study Status and Contacts/Locations
26 April 9, 2018 Contacts/Locations and Study Status
27 May 7, 2018 Contacts/Locations and Study Status
28 October 2, 2018 Contacts/Locations, References and Study Status
29 November 27, 2018 Contacts/Locations and Study Status
30 January 30, 2019 Contacts/Locations and Study Status
31 May 28, 2019 Contacts/Locations and Study Status
32 September 19, 2019 Arms and Interventions, Study Status, Contacts/Locations, Outcome Measures, Eligibility and Study Design
33 October 24, 2019 Arms and Interventions, Study Status and Sponsor/Collaborators
34 December 5, 2019 Contacts/Locations and Study Status
35 April 24, 2020 Contacts/Locations and Study Status
36 May 20, 2020 Contacts/Locations and Study Status
37 June 9, 2020 Study Status
38 June 15, 2020 Contacts/Locations and Study Status
39 August 24, 2020 Contacts/Locations and Study Status
40 July 14, 2021 Recruitment Status, Contacts/Locations, Study Status, Arms and Interventions and Study Design
41 January 20, 2022 Arms and Interventions, Study Status, Contacts/Locations, Eligibility, Outcome Measures, References, Study Design, Study Description and Study Identification
42 March 17, 2022 Study Status
43 April 13, 2022 Contacts/Locations and Study Status
44 May 5, 2022 Study Status and Contacts/Locations
45 August 18, 2022 Contacts/Locations and Study Status
46 November 30, 2022 Study Status and Contacts/Locations
47 May 9, 2023 Recruitment Status, Study Status, Outcome Measures, Document Section, Results and Contacts/Locations
Comparison Format:

Scroll up to access the controls

Study NCT02935634
Submitted Date:  April 13, 2022 (v43)

Open or close this module Study Identification
Unique Protocol ID: CA018-003
Brief Title: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (FRACTION-GC)
Official Title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Secondary IDs: 2016-002807-24 [EudraCT Number]
Open or close this module Study Status
Record Verification: April 2022
Overall Status: Active, not recruiting
Study Start: November 29, 2016
Primary Completion: May 21, 2023 [Anticipated]
Study Completion: May 21, 2023 [Anticipated]
First Submitted: October 14, 2016
First Submitted that
Met QC Criteria:
October 14, 2016
First Posted: October 17, 2016 [Estimate]
Last Update Submitted that
Met QC Criteria:
April 13, 2022
Last Update Posted: April 15, 2022 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Bristol-Myers Squibb
Responsible Party: Sponsor
Collaborators: Clovis Oncology, Inc.
Open or close this module Oversight
U.S. FDA-regulated Drug: Yes
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.
Detailed Description:
Open or close this module Conditions
Conditions: Advanced Gastric Cancer
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Parallel Assignment
Number of Arms: 6
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 190 [Actual]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Active Comparator: Nivolumab + Ipilimumab Biological: Nivolumab
Specified dose on specified days
Other Names:
  • Opdivo
  • BMS-936558
Biological: Ipilimumab
Specified dose on specified days
Other Names:
  • Yervoy
  • BMS-734016
Experimental: Nivolumab + Relatlimab Biological: Nivolumab
Specified dose on specified days
Other Names:
  • Opdivo
  • BMS-936558
Biological: Relatlimab
Specified dose on specified days
Other Names:
  • BMS-986016
Experimental: Nivolumab + BMS-986205 Biological: Nivolumab
Specified dose on specified days
Other Names:
  • Opdivo
  • BMS-936558
Biological: BMS-986205
Specified dose on specified days
Experimental: Nivolumab + Rucaparib Biological: Nivolumab
Specified dose on specified days
Other Names:
  • Opdivo
  • BMS-936558
Drug: Rucaparib
Specified dose on specified days
Other Names:
  • Rubraca
Experimental: Ipilimumab + Rucaparib Biological: Ipilimumab
Specified dose on specified days
Other Names:
  • Yervoy
  • BMS-734016
Drug: Rucaparib
Specified dose on specified days
Other Names:
  • Rubraca
Experimental: Nivolumab + Ipilimumab + Rucaparib Biological: Nivolumab
Specified dose on specified days
Other Names:
  • Opdivo
  • BMS-936558
Biological: Ipilimumab
Specified dose on specified days
Other Names:
  • Yervoy
  • BMS-734016
Drug: Rucaparib
Specified dose on specified days
Other Names:
  • Rubraca
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator
[ Time Frame: Up to 24 months ]

2. Duration of Response (DOR) by RECIST v1.1 by Investigator
[ Time Frame: Up to 24 months ]

3. Progression-free Survival Rate (PFSR)
[ Time Frame: Up to 24 months ]

4. Incidence of Adverse Events (AEs) in Part 1
[ Time Frame: Approximately 28 Months ]

5. Incidence of Serious Adverse Events (SAEs) in Part 1
[ Time Frame: Approximately 28 Months ]

6. Incidence of AEs leading to discontinuation in Part 1
[ Time Frame: Approximately 28 Months ]

7. Incidence of deaths in Part 1
[ Time Frame: Approximately 28 Months ]

8. Incidence of participants with clinical laboratory abnormalities in Part 1
[ Time Frame: Approximately 28 Months ]

Secondary Outcome Measures:
1. Incidence of AEs
[ Time Frame: Approximately 28 months ]

2. Incidence of SAEs
[ Time Frame: Approximately 28 months ]

3. Incidence of AEs leading to discontinuation
[ Time Frame: Approximately 28 months ]

4. Incidence of AEs leading to death
[ Time Frame: Approximately 28 months ]

5. Incidence of participants with clinical laboratory test abnormalities
[ Time Frame: Approximately 28 Months ]

Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • Inoperable, advanced or metastatic esophageal cancer (EC), gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma and have histologically confirmed predominant adenocarcinoma and/or squamous carcinoma
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • At least 1 lesion with measurable disease

Exclusion Criteria:

  • HER2-positive tumor and previously untreated with trastuzumab
  • Suspected, known or progressive central nervous system metastases
  • Other active malignancy requiring concurrent intervention
  • Active, known or suspected autoimmune disease

Other protocol-defined inclusion/exclusion criteria apply

Open or close this module Contacts/Locations
Study Officials: Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Locations: United States, Arizona
Mayo Clinic Arizona
Phoenix, Arizona, United States, 85054
United States, California
City Of Hope National Medical Center
Duarte, California, United States, 91010-3000
United States, Colorado
University Of Colorado
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06520
United States, District of Columbia
Local Institution - 0036
Washington, District of Columbia, United States, 20007
United States, Florida
UF Health Medical Oncology - Davis Cancer Pavilion
Gainesville, Florida, United States, 32610
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
United States, Maryland
John Hopkins
Baltimore, Maryland, United States, 21224
United States, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Local Institution - 0001
Hackensack, New Jersey, United States, 07601
United States, New York
Memorial Sloan Kettering Nassau
New York, New York, United States, 10065
United States, Oregon
Local Institution - 0002
Portland, Oregon, United States, 97225
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
UPMC
Pittsburgh, Pennsylvania, United States, 15232
United States, Washington
Local Institution - 0004
Seattle, Washington, United States, 98109
Australia
Local Institution
Randwick, Australia, 2031
Australia, New South Wales
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Australia, Victoria
Austin Health-Cancer Clinical Trials Centre
Heidelberg, Victoria, Australia, 3084
Canada, Alberta
Local Institution
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Local Institution
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Local Institution
Ottawa, Ontario, Canada, K1H 8L6
Local Institution
Toronto, Ontario, Canada, M5G 2M9
Sunnybrook Research Institution
Toronto,, Ontario, Canada, M4N 3M5
Germany
Nationales Centrum Fur Tumorerkrankungen (Nct)
Heidelberg, Germany, 69120
Universitaetsklinikum Leipzig
Leipzig, Germany, 04103
Israel
Local Institution
Ramat Gan, Israel, 52621
Local Institution
Tel Aviv, Israel, 64239
Italy
Istituto Europeo Di Oncologia
Milan, Italy, 20141
IRCCS Istituto Nazionale Tumori Milano
Milano, Italy, 20133
Netherlands
Local Institution
Amsterdam, Netherlands, 1081 HV
Local Institution
Utrecht, Netherlands, 3584 CX
Singapore
Local Institution
Singapore, Singapore, 169610
Switzerland
University Hospital Zuerich
Zuerich, Switzerland, 8091
Switzerland, Graubünden (de)
Local Institution - 0041
Chur, Graubünden (de), Switzerland, 7000
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links: Description: BMS Clinical Trial Information
Description: BMS Clinical Trial Patient Recruiting
Description: Investigator Inquiry Form
Description: FDA Safety Alerts and Recalls
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services